hotspot -WSS

hotspot

author：entertainment 2025-10-01 01:00:36 - browse：36147

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Readout Newsletter: Amgen, Regeneron, BGI Group and more

hotspot

Wikipedia

WSS

A protest over insulin prices is seen as a fight for life

Adopting new red light myopia treatments may be short

Listen: BridgeBio's big week & Lilly's Alzheimer's data

Florida babysitter arrested over hot car death, authorities say

A new deal aims to ramp up use of AI in rehab care decisions

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

focus

hotspot

focus

After affirmative action ruling, medical educators look to 'holistic review'

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Psychedelics group wrestles with new pharma identity

Suspects arrested after 3 women attacked on Manhattan's West Side: Police

Alkermes shareholders re

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Medicare proposal to cover medical devices draws a mixed reaction

A former Republican legislative candidate has been charged for his role in the US Capitol riot

New air purifier tech could be key to improving indoor air quality

Problems with a popular proposal to regulate AI in health care

hotspot

The Biogen Aduhelm mess could happen again

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

Johnson & Johnson sued for allegedly overpaying for workers' drugs

AstraZeneca stays mum on Medicare drug pricing negotiations

The biotech scorecard for the 2nd quarter: 12 industry events to watch

A former Republican legislative candidate has been charged for his role in the US Capitol riot

hotspot

focus

Wikipedia

leisure time